Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are
the leading causes of blindness worldwide. The mainstay of treatment for these blinding …

Drug discovery for ocular diseases has taken great strides in the last two decades. From
cornea to choroid, new drugs have been formulated to address a great variety of ocular …

The vitreous humor represents a significant barrier to the penetration of nanoparticulate-
based ocular drug delivery systems. The gel structure and biochemical components of the …

Various efforts in ocular drug delivery have been made to improve the bioavailability and to
prolong the residence time of drugs applied topically onto the eye. The potential use of …

The eye consists of sensitive, compactly adjoined tissue structures which act as strong
physical (static) and physiological (dynamic) barriers that prevent entry of foreign bodies into …

Despite numerous scientific efforts, efficient ocular drug delivery remains a challenge for
pharmaceutical scientists. Most ocular diseases are treated by topical drug application in the …

The following sections are included: Biopharmaceutical Barriers in Ocular Drug Delivery.
Classification of Nanoparticulate Carriers for Ocular Drug Delivery Nanoparticulate Polymer …

In current drug delivery scenario, despite numerous scientific efforts, efficient ocular drug
delivery remains a challenge for pharmaceutical scientists. In ocular drug delivery system …

Ocular drug delivery is one of the most challenging areas of drug delivery due to the unique
mostly avascular nature of the major eye structures and presence of two blood barriers …

Microparticulates are drug-containing small polymeric particles (erodible, non-erodible or
ion-exchange resins) that are suspended in a liquid carrier medium. Upon administration of …